Profile data is unavailable for this security.
About the company
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
- Revenue in USD (TTM)0.00
- Net income in USD-16.87m
- Incorporated2021
- Employees7.00
- LocationIndaptus Therapeutics Inc3 Columbus Circle, 15Th FloorNEW YORK 10019United StatesUSA
- Phone+1 (302) 485-3907
- Websitehttps://indaptusrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GRI Bio Inc | 0.00 | -11.96m | 3.34m | 4.00 | -- | 0.1914 | -- | -- | -248.19 | -248.19 | 0.00 | 12.07 | 0.00 | -- | -- | 0.00 | -166.00 | -190.54 | -236.14 | -330.83 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.17 | -- | 8.45 | -- |
| Vaccinex Inc | 601.00k | -18.63m | 3.35m | 23.00 | -- | -- | -- | 5.57 | -9.91 | -9.91 | 0.2864 | -0.9295 | 0.193 | -- | 0.6682 | 26,130.44 | -598.49 | -299.11 | -- | -- | -- | -- | -3,100.50 | -3,700.14 | -- | -149.88 | -- | -- | 5.44 | 2.82 | 7.98 | -- | -22.36 | -- |
| Burzynski Research Institute Inc | 0.00 | -1.29m | 3.42m | 2.00 | -- | -- | -- | -- | -0.0098 | -0.0098 | 0.00 | -0.0005 | 0.00 | -- | -- | -- | -86,374.50 | -28,790.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.80 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 3.55m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| AIM ImmunoTech Inc | 112.00k | -15.75m | 3.57m | 21.00 | -- | -- | -- | 31.87 | -19.82 | -19.82 | 0.1067 | -2.20 | 0.0117 | -- | -- | 5,333.33 | -165.08 | -50.43 | -637.78 | -55.23 | 15.18 | -113.19 | -14,062.50 | -12,238.47 | -- | -- | -- | -- | -15.84 | 3.96 | 40.20 | -- | -45.22 | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -16.87m | 3.78m | 3.00 | -- | 0.539 | -- | -- | -3.30 | -3.30 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -111.43 | -49.82 | -126.56 | -54.00 | -- | -- | -- | -2,545.33 | -- | -- | 0.0025 | -- | -100.00 | -- | -5.71 | -- | -- | -- |
| Nymox Pharmaceutical Corp | -100.00bn | -100.00bn | 3.80m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -0.0717 | -- | -- | -- | -- | -- | -397.74 | -- | -- | -- | -- | -- | -883,740.00 | -- | -- | -- | -- | -- | -- | 49.21 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -671.75k | 3.83m | 2.00 | -- | -- | -- | -- | -0.0928 | -0.0928 | 0.00 | -1.01 | 0.00 | -- | -- | 0.00 | -1,410.50 | -- | -- | -- | -- | -- | -- | -- | -- | -7.37 | -- | -- | -- | -- | 8.56 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -14.08m | 3.86m | 8.00 | -- | 0.1198 | -- | -- | -120.02 | -120.02 | 0.00 | 12.27 | 0.00 | -- | -- | 0.00 | -82.96 | -- | -118.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12,406.06 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -5.08m | 3.88m | -- | -- | 0.6078 | -- | 53.74 | -0.9262 | -0.9262 | 0.0117 | 0.4788 | 0.0097 | -- | -- | -- | -67.91 | -29.61 | -76.93 | -32.10 | 65.24 | 92.17 | -7,039.37 | -3,630.72 | -- | -- | 0.00 | -- | 0.00 | 12.19 | -20.98 | -- | -- | -- |
| Clearside Biomedical Inc | 3.33m | -26.00m | 3.92m | 32.00 | -- | -- | -- | 1.18 | -5.06 | -5.06 | 0.6461 | -10.31 | 0.1632 | -- | 6.32 | 104,031.30 | -127.43 | -67.79 | -160.28 | -84.94 | 88.07 | -- | -780.90 | -241.58 | -- | -- | 8.48 | -- | -79.77 | -5.20 | -5.75 | -- | 108.16 | -- |
| Indaptus Therapeutics Inc | 0.00 | -16.87m | 3.95m | 7.00 | -- | 0.6274 | -- | -- | -31.67 | -31.67 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -223.71 | -56.08 | -317.86 | -68.84 | -- | -- | -- | -- | -- | -13.74 | 0.00 | -- | -- | -- | 2.60 | -- | -- | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -8.70m | 4.03m | 3.00 | -- | 0.1757 | -- | -- | -3.60 | -3.60 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -40.91 | -55.02 | -46.34 | -64.19 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.75 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -8.01m | 4.09m | 21.00 | -- | 16.12 | -- | -- | -13.35 | -13.35 | 0.00 | 0.2178 | 0.00 | -- | -- | 0.00 | -154.83 | -132.71 | -183.46 | -155.93 | -- | -- | -- | -- | 1.31 | -- | 0.00 | -- | -- | -- | -14.39 | -- | -18.17 | -- |
| Aprea Therapeutics Inc | 488.24k | -13.04m | 4.26m | 8.00 | -- | 0.3339 | -- | 8.73 | -2.14 | -2.14 | 0.08 | 1.95 | 0.0237 | -- | -- | 61,030.00 | -63.27 | -81.97 | -74.72 | -94.17 | -- | -- | -2,670.56 | -11,051.52 | -- | -- | 0.00 | -- | 157.63 | -- | 9.30 | -- | -12.91 | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 148.34k | -555.16k | 4.65m | 2.00 | -- | -- | -- | 31.35 | -0.00006 | -0.00006 | 0.00001 | -0.0001 | 4.55 | -- | 11.35 | 74,170.00 | -1,702.42 | -652.66 | -- | -- | 73.11 | 87.76 | -374.25 | -177.59 | -- | -4.30 | -- | -- | 21.77 | 0.8662 | 15.74 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Indaptus Therapeutics Inc's reporting currency: US Dollar USD
4.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Yorkville Advisors LLCas of 13 Feb 2025 | 50.39k | 2.25% |
| UBS Securities LLCas of 31 Dec 2025 | 29.00k | 1.29% |
| Virtu Americas LLCas of 30 Sep 2025 | 19.00k | 0.85% |
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 9.21k | 0.41% |
| Tower Research Capital LLCas of 30 Sep 2025 | 473.00 | 0.02% |
| BofA Securities, Inc.as of 30 Sep 2025 | 28.00 | 0.00% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 17.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 5.00 | 0.00% |
| Strategic Advisers LLCas of 30 Sep 2025 | 0.00 | 0.00% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 12 Jan 2026Source: FactSet Research Systems Inc.
